Gold standard medical therapy for glaucoma: Defining the criteria identifying measures for an evidence-based analysis

Clinical Therapeutics

Volumn 26, Issue 12, 2004, Pages 2102-2120

  Obstbaum, Stephen A ^a,r   Cioffi, George A ^b   Krieglstein, Guenther K ^c   Fennerty, M Brian ^d   Alm, Albert ^e   Araie, Makoto ^f   Carassa, Roberto G ^g   Greve, Erik L ^h   Hitchings, Roger A ⁱ   Kaufman, Paul L ^j   Kitazawa, Yoshiaki ^k   Pongpun, Prin Rojana ^l   Susanna Jr , Remo ^m   Wax, Martin B ^n,o,p   Zimmerman, Thom J ^n,q  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DEVERS EYE INSTITUTE   (United States)

^c UNIVERSITY OF COLOGNE   (Germany)

^d OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^e UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^f UNIVERSITY OF TOKYO HOSPITAL   (Japan)

^g SAN RAFFAELE HOSPITAL   (Italy)

^h UNIVERSITY OF AMSTERDAM   (Netherlands)

ⁱ MOORFIELDS EYE HOSPITAL   (United Kingdom)

^j UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^k GIFU UNIVERSITY   (Japan)

^l CHULALONGKORN UNIVERSITY   (Thailand)

^m UNIVERSITY OF SÃO PAULO   (Brazil)

ⁿ PFIZER INC   (United States)

^o WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^p Alcon Research Inc   (United States)

^q University of Louisville School of Medicine   (United States)

^r NONE   (United States)

more..

Author keywords

Beta adrenergic blockers; Evidence based medicine; Gold standard; Intraocular pressure; Open angle glaucoma; Prostaglandin

Indexed keywords

ACETYLSALICYLIC ACID; ACICLOVIR; ADRENALIN; ADRENERGIC RECEPTOR STIMULATING AGENT; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; ALTEPLASE; AMPHOTERICIN B; ANTIGLAUCOMA AGENT; ANTIHYPERTENSIVE AGENT; APRACLONIDINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BOTULINUM TOXIN; BRINZOLAMIDE; CARBACHOL; CARBONATE DEHYDRATASE INHIBITOR; CHOLINERGIC RECEPTOR STIMULATING AGENT; DIPIVEFRINE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LEVODOPA; METHOTREXATE; NIFEDIPINE; OMEPRAZOLE; PILOCARPINE; PROSTAGLANDIN DERIVATIVE; PROTON PUMP INHIBITOR; SUMATRIPTAN; TAMOXIFEN; TIMOLOL;

ARTERY THROMBOSIS; BLOOD CLOT LYSIS; BRADYCARDIA; BREAST CANCER; CHOLESTEROL BLOOD LEVEL; CHRONIC DISEASE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; EPIDEMIOLOGICAL DATA; EVIDENCE BASED MEDICINE; FACE DISORDER; GASTROESOPHAGEAL REFLUX; GENITAL HERPES; GLAUCOMA; HEALTH ECONOMICS; HUMAN; INTRAOCULAR PRESSURE; JUVENILE RHEUMATOID ARTHRITIS; LUNG FUNCTION; MEDICAL DECISION MAKING; MEDICAL LITERATURE; MEDLINE; MENTAL DISEASE; MIGRAINE; OPEN ANGLE GLAUCOMA; OPHTHALMOLOGY; OPTIC NERVE; PARKINSON DISEASE; PATIENT COMPLIANCE; PATIENT EDUCATION; PRACTICE GUIDELINE; PUBLICATION; QUALITY OF LIFE; REVIEW; RISK BENEFIT ANALYSIS; RISK FACTOR; SCLERODERMA; SIDE EFFECT; STANDARDIZATION; SYSTEMATIC REVIEW; TACHYPHYLAXIS; THORAX PAIN; VALIDATION PROCESS; VISUAL FIELD;

EID: 20144372782     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clintera.2004.12.007     Document Type: Article

References (154)

1. Hoffman C, Rice D, and Sung HY Persons with chronic conditions. Their prevalence and costs JAMA 276 1996 1473 1479
2. Druss BG, Marcus SC, and Olfson M Comparing the national economic burden of five chronic conditions Health Aff (Millwood) 20 2001 233 241
3. Epping-Jordan J, Bengoa R, Kawar R, and Sabate E The challenge of chronic conditions: WHO responds BMJ 323 2001 947 948
4. [online]. Available at: Institute of Medicine Crossing the Quality Chasm: A New Health System for the 21st Century Accessed August 25, 2004 2001
5. [online]. Available at: Institute of Medicine Leadership by Example: Coordinating Government Roles in Improving Health Care Quality Accessed August 25, 2004 2002
6. Casalino L, Gillies RR, and Shortell SM External incentives, information technology, and organized processes to improve health care quality for patients with chronic diseases JAMA 289 2003 434 441
7. Coye MJ No Toyotas in health care: Why medical care has not evolved to meet patients' needs Health Aff (Millwood) 20 2001 44 56
8. Eddy DM, and Billings J The quality of medical evidence: Implications for quality of care Health Aff (Millwood) 7 1988 19 32
9. Dunbar-Jacob J, and Mortimer-Stephens MK Treatment adherence in chronic disease J Clin Epidemiol. 54 Suppl 1 2001 557 560
10. American Academy of Ophthalmology Preferred Practice Patterns Glaucoma Panel Preferred Practice Pattern: Primary Open-Angle Glaucoma 2000 American Academy of Ophthalmology Stamford, Conn 13 14
11. European Glaucoma Society Terminology and Guidelines for Glaucoma 2nd ed. 2003 European Glaucoma Society San Francisco, Calif
12. Friedman DS, Wolfs RC, O'Colmain BJ Eye Diseases Prevalence Research Group Prevalence of open-angle glaucoma among adults in the United States Arch Ophthalmol. 122 2004 532 538
13. World Health Organization (WHO) World Health Report 1997: Executive Summary: Conquering suffering, enriching humanity August 27, 2004 [WHO Web site]. Available at: Accessed
14. Thylefors B, and Negrel AD The global impact of glaucoma Bull World Health Organ. 72 1994 323 326
15. World Health Organization (WHO) The World Health Report 2001: Mental Health: New Understanding, New Hope 2001 WHO Savona, Italy 152 153
16. Sommer A, Tielsch JM, and Katz J Relationship between intraocular pressure and primary open angle glaucoma among white and black Americans. The Baltimore Eye Survey Arch Ophthalmol. 109 1991 1090 1095
17. Viswanathan AC, McNaught AI, and Poinoosawmy D Severity and stability of glaucoma: Patient perception compared with objective measurement Arch Ophthalmol. 117 1999 450 454
18. Jampel HD, Friedman DS, Quigley H, and Miller R Correlation of the binocular visual field with patient assessment of vision Invest Ophthalmol Vis. Sci. 43 2002 1059 1067
19. Kook MS, Sung K, and Kim S Study of retinal nerve fibre layer thickness in eyes with high tension glaucoma and hemifield defect Br J Ophthalmol. 85 2001 1167 1170
20. Matsumoto C, Shirato S, and Haneda M Study of retinal nerve fiber layer thickness within normal hemivisual field in primary open-angle glaucoma and normal-tension glaucoma Jpn J Ophthalmol. 47 2003 22 27
21. Sommer A, Katz J, and Quigley HA Clinically detectable nerve fiber atrophy precedes the onset of glaucomatous field loss Arch Ophthalmol. 109 1991 77 83
22. Lichter PR Testimony before Department of Labor, Health and Human Services, and Related Agencies Presented at the 1st US Congress House Committee on Appropriations for 1993 1992 Government Printing Office Geneva, Switzerland 1317 1330
23. Abrams LS, Scott IU, and Spaeth GL Agreement among optometrists, ophthalmologists, and residents in evaluating the optic disc for glaucoma Ophthalmology 101 1994 1662 1667
24. American Academy of Ophthalmology Optic nerve head and retinal nerve fiber layer analysis Ophthalmology 106 1999 1414 1424
25. Sanchez-Galeana C, Bowd C, and Blumenthal EZ Using optical imaging summary data to detect glaucoma Ophthalmology 108 2001 1812 1818
26. Zangwill LM, Bowd C, and Berry CC Discriminating between normal and glaucomatous eyes using the Heidelberg Retina Tomograph, GDx Nerve Fiber Analyzer, and Optical Coherence Tomograph Arch Ophthalmol 119 2001 985 993
27. Schulzer M Errors in the diagnosis of visual field progression in normal-tension glaucoma Ophthalmology 101 1994 1589 1595
28. Bayer AU, and Erb C Short wavelength automated perimetry, frequency doubling technology perimetry, and pattern electroretinography for prediction of progressive glaucomatous standard visual field defects Ophthalmology 109 2002 1009 1017
29. Delgado MF, Nguyen NT, Cox TA American Academy of Ophthalmology Ophthalmic Technology Assessment Committee 2001-2002 Glaucoma Panel Automated perimetry: A report by the American Academy of Ophthalmology Ophthalmology 109 2002 2362 2374
30. Iester M, Altieri M, and Vittone P Detection of glaucomatous visual field defect by nonconventional perimetry Am J Ophthalmol. 135 2003 35 39
31. Johnson CA, Sample PA, and Cioffi GA Structure and function evaluation (SAFE): I. Criteria for glaucomatous visual field loss using standard automated perimetry (SAP) and short wavelength automated perimetry (SWAP) Am J Ophthalmol. 134 2002 177 185
32. Moss ID, Wild JM, and Whitaker DJ The influence of age-related cataract on blue-on-yellow perimetry Invest Ophthalmol Vis Sci. 36 1995 764 773
33. Bowd C, Zangwill LM, and Berry CC Detecting early glaucoma by assessment of retinal nerve fiber layer thickness and visual function Invest Ophthalmol Vis Sci. 42 2001 1993 2003
34. Quigley HA Identification of glaucoma-related visual field abnormality with the screening protocol of frequency doubling technology Am J Ophthalmol. 125 1998 819 829
35. Mao LK, Stewart WC, and Shields MB Correlation between intraocular pressure control and progressive glaucomatous damage in primary open-angle glaucoma Am J Ophthalmol. 111 1991 51 55
36. Rath EZ, Shin DH, and Kim C Relationship between optic disc cupping change and intraocular pressure control in adult glaucoma patients Graefes Arch Clin Exp Ophthalmol. 234 1996 434 439
37. Tanito M, Itai N, and Dong J Correlation between intraocular pressure level and optic disc changes in high-tension glaucoma suspects Ophthalmology 110 2003 915 921
38. Lichter PR, Musch DC, Gillespie BW for the CIGTS Study Group Interim clinical outcomes in the Collaborative Initial Glaucoma Treatment Study comparing initial treatment randomized to medications or surgery Ophthalmology 108 2001 1943 1953
39. The AGIS Investigators The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration Am J Ophthalmol. 130 2000 429 440
40. Kass MA, Heuer DK, and Higginbotham EJ The Ocular Hypertension Treatment Study: A randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma Arch Ophthalmol. 120 2002 701 713
41. Gordon MO, Beiser JA, and Brandt JD The Ocular Hypertension Treatment Study: Baseline factors that predict the onset of primary open-angle glaucoma Arch Ophthalmol. 120 2002 714 720
42. [published correction appears in Am J Ophthalmol. 1999;127:120] Collaborative Normal-Tension Glaucoma Study Group Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures Am J Ophthalmol. 126 1998 487 497
43. Heijl A, Leske MC, Bengtsson B Early Manifest Glaucoma Trial Group Reduction of intraocular pressure and glaucoma progression: Results from the Early Manifest Glaucoma Trial Arch Ophthalmol. 120 2002 1268 1279
44. Leske MC, Heijl A, Hussein M Early Manifest Glaucoma Trial Group Factors for glaucoma progression and the effect of treatment: The early manifest glaucoma trial Arch Ophthalmol. 121 2003 48 56
45. Caprioli J Criteria for success of surgical treatment of glaucoma Curr Opin Ophthalmol. 8 1997 68 72
46. Gotzsche PC, Liberati A, Torri V, and Rossetti L Beware of surrogate outcome measures Int J Technol Assess Health Care 12 1996 238 246
47. McAlister FA, Straus SE, Guyatt GH, Haynes RB Evidence-Based Medicine Working Group Users' Guides to the Medical Literature: XX. Integrating research evidence with the care of the individual patient JAMA 283 2000 2829 2836
48. Guyatt GH, Haynes RB, Jaeschke RZ Evidence-Based Medicine Working Group Users' Guides to the Medical Literature: XXV. Evidence-based medicine: Principles for applying the Users' Guides to patient care JAMA 284 2000 1290 1296
49. Eddy DM A Manual for Assessing Health Practices & Designing Practice Policies: The Explicit Approach 1992 American College of Physicians Washington, DC 21
50. Meinert CL Clinical trials: The gold standard for evaluation of therapy Ophthalmology 103 1996 869 870
51. Rossetti L, Marchetti I, and Orzalesi N Randomized clinical trials on medical treatment of glaucoma. Are they appropriate to guide clinical practice? Arch Ophthalmol 111 1993 96 103
52. Davidoff F, Haynes B, Sackett D, and Smith R Evidence based medicine BMJ 310 1995 1085 1086
53. Eddy DM Practice policies: Where do they come from? JAMA 263 1990 1265 1272
54. European Glaucoma Society Terminology and Guidelines for Glaucoma 1998 European Glaucoma Society Philadelphia, Pa
55. Carruthers A, and Carruthers J Botulinum toxin type A: History and current cosmetic use in the upper face Semin Cutan Med Surg. 20 2001 71 84
56. Fornier M, Munster P, and Seidman AD Update on the management of advanced breast cancer Oncology (Huntingt) 13 1999 647 658
57. Geers TA, and Isada CM Update on antiviral therapy for genital herpes infection Cleve Clin J Med 67 2000 567 573
58. Goadsby PJ The scientific basis of medication choice in symptomatic migraine treatment Can J Neurol Sci. 26 Suppl 3 1999 S20 S26
59. Koller WC Levodopa in the treatment of Parkinson's disease Neurology 55 Suppl 4 2000 S2 S7
60. Leeb BF, and Smolen JS Low dose methotrexate therapy in chronic polyarthritis--an update [in German] Acta Med Austriaca 23 1996 114 119
61. Leighton C Drug treatment of scleroderma Drugs 61 2001 419 427
62. Leung DT, and Sacks SL Current recommendations for the treatment of genital herpes Drugs 60 2000 1329 1352
63. Meis JFGM, and Verweij PE Current management of fungal infections Drugs 61 Suppl 1 2001 13 25
64. Nordt TK, and Bode C Optimal thrombolysis [in German] Z Kardiol 90 2001 591 595
65. Schepp W Proton pump inhibitory therapy: Then and now Yale J Biol Med. 69 1996 175 186
66. Schr r K Aspirin and platelets: The antiplatelet action of aspirin and its role in thrombosis treatment and prophylaxis Semin Thromb Hemost 23 1997 349 356
67. Tan AK Current and emerging treatments in Parkinson's disease Ann Acad Med Singapore 30 2001 128 133
68. Tiphine M, Letscher-Bru V, and Herbrecht R Amphotericin B and its new formulations: Pharmacologic characteristics, clinical efficacy, and tolerability Transpl Infect Dis. 1 1999 273 283
69. Van De Graaff E, and Steinhubl SR Antiplatelet medications and their indications in preventing and treating coronary thrombosis Ann Med. 32 2000 561 571
70. Wise GJ Genitourinary fungal infections: A therapeutic conundrum Expert Opin Pharmacother. 2 2001 1211 1226
71. DeVault KR, Castell DO, and Practice Parameters Committee of the American College of Gastroenterology Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease Am J Gastroenterol 94 1999 1434 1442
72. Armstrong D, Nicolet M, and Monnier P Maintenance therapy: Is there still a place for antireflux surgery? World J Surg. 16 1992 300 307
73. Fennerty MB Helicobacter pylori Arch Intern Med. 154 1994 721 727
74. Schenk BE, Kuipers EJ, and Klinkenberg-Knol EC Omeprazole as a diagnostic tool in gastroesophageal reflux disease Am J Gastroenterol 92 1997 1997 2000
75. Sontag SJ Rolling review: Gastro-oesophageal reflux disease Aliment Pharmacol Ther. 7 1993 293 312
76. Locke GR III, Talley NJ, and Fett SL Prevalence and clinical spectrum of gastroesophageal reflux: A population-based study in Olmsted County, Minnesota Gastroenterology 112 1997 1448 1456
77. Dimenes E Methodological aspects of evaluation of quality of life in upper gastrointestinal diseases Scand J Gastroenterol Suppl. 199 1993 18 21
78. Obstbaum SA, Galin MA, and Katz IM Timolol: Effect on intraocular pressure in chronic open-angle glaucoma Ann Ophthalmol. 10 1978 1347 1351
79. Radius RL, Diamond GR, Pollack IP, and Langham ME Timolol. A new drug for management of chronic simple glaucoma Arch Ophthalmol 96 1978 1003 1008
80. Zimmerman TJ, and Kaufman HE Timolol. A beta-adrenergic blocking agent for the treatment of glaucoma Arch Ophthalmol 95 1977 601 604
81. Novack GD Ophthalmic beta-blockers since timolol Surv Ophthalmol 31 1987 307 327
82. Alward WL Medical management of glaucoma N Engl J Med 339 1998 1298 1307
83. [published correction appears in Drugs. 2002;62:1314] Hoyng PF, and van Beek LM Pharmacological therapy for glaucoma: A review Drugs 59 2000 411 434
84. Zimmerman TJ, Kass MA, Yablonski ME, and Becker B Timolol maleate: Efficacy and safety Arch Ophthalmol 97 1979 656 658
85. Hayreh SS, Podhajsky P, and Zimmerman MB Beta-blocker eyedrops and nocturnal arterial hypotension Am J Ophthalmol 128 1999 301 309
86. Coleman AL, Diehl DL, and Jampel HD Topical timolol decreases plasma high-density lipoprotein cholesterol level Arch Ophthalmol 108 1990 1260 1263
87. [published correction appears in Lancet. 1995;346:322] Diggory P, Cassels-Brown A, and Vail A Avoiding unsuspected respiratory side-effects of topical timolol with cardioselective or sympathomimetic agents Lancet 345 1995 1604 1606
88. Shore JH, Fraunfelder FT, and Meyer SM Psychiatric side effects from topical ocular timolol, a beta-adrenergic blocker J Clin Psychopharmacol 7 1987 264 267
89. Van Buskirk EM Adverse reactions from timolol administration Ophthalmology 87 1980 447 450
90. Uusitalo RJ, and Palkama A Long-term evaluation of timolol Acta Ophthalmol (Copenh) 67 1989 573 581
91. Orzalesi N, Rossetti L, and Invernizzi T Effect of timolol, latanoprost, and dorzolamide on circadian IOP in glaucoma or ocular hypertension Invest Ophthalmol Vis Sci 41 2000 2566 2573
92. Leske MC, Connell AM, Wu SY Barbados Eye Studies Group Incidence of open-angle glaucoma: The Barbados Eye Studies Arch Ophthalmol 119 2001 89 95
93. Leske MC, Connell AM, and Wu SY Risk factors for open-angle glaucoma. The Barbados Eye Study Arch Ophthalmol 113 1995 918 924
94. Quigley HA, Tielsch JM, Katz J, and Sommer A Rate of progression in open-angle glaucoma estimated from cross-sectional prevalence of visual field damage Am J Ophthalmol 122 1996 355 363
95. Suzuki Y, Shirato S, Adachi M, and Hamada C Risk factors for the progression of treated primary open-angle glaucoma: A multivariate life-table analysis Graefes Arch Clin Exp Ophthalmol 237 1999 463 467
96. Collaborative Normal-Tension Glaucoma Study Group The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma Am J Ophthalmol 126 1998 498 505
97. Shirakashi M, Iwata K, and Sawaguchi S Intraocular pressure-dependent progression of visual field loss in advanced primary open-angle glaucoma: A 15-year follow-up Ophthalmologica 207 1993 1 5
98. Stewart WC, Kolker AE, and Sharpe ED Factors associated with long-term progression or stability in primary open-angle glaucoma Am J Ophthalmol 130 2000 274 279
99. Heijl A, and Bengtsson B Long-term effects of timolol therapy in ocular hypertension: A double-masked, randomised trial Graefes Arch Clin Exp Ophthalmol 238 2000 877 883
100. Asrani S, Zeimer R, and Wilensky J Large diurnal fluctuations in intraocular pressure are an independent risk factor in patients with glaucoma J Glaucoma 9 2000 134 142
101. Bergea B, Bodin L, and Svedbergh B Impact of intraocular pressure regulation on visual fields in open-angle glaucoma Ophthalmology 106 1999 997 1004
102. Zeimer RC, Wilensky JT, Gieser DK, and Viana MA Association between intraocular pressure peaks and progression of visual field loss Ophthalmology 98 1991 64 69
103. DuBiner HB, Mroz M, Shapiro AM Brimonidine vs. Latanoprost Study Group A comparison of the efficacy and tolerability of brimonidine and latanoprost in adults with open-angle glaucoma or ocular hypertension: A three-month, multicenter, randomized, double-masked, parallel-group trial Clin Ther 23 2001 1969 1983
104. Netland PA, Landry T, Sullivan EK Travoprost Study Group Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension Am J Ophthalmol 132 2001 472 484
105. Parrish RK, Palmberg P, Sheu WP XLT Study Group A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: A 12-week, randomized, masked-evaluator multicenter study Am J Ophthalmol 135 2003 688 703
106. Simmons ST, Earl ML Alphagan/Xalatan Study Group Three-month comparison of brimonidine and latanoprost as adjunctive therapy in glaucoma and ocular hypertension patients uncontrolled on beta-blockers: Tolerance and peak intraocular pressure lowering Ophthalmology 109 2002 307 314
107. Chung HS, Harris A, and Evans DW Vascular aspects in the pathophysiology of glaucomatous optic neuropathy Surv Ophthalmol 43 Suppl 1 1999 S43 S50
108. Vidal-Sanz M, Lafuente MP, and Mayor-Torroglosa S Brmonidine's neuroprotective effects against transient ischaemia-induced retinal ganglion cell death Eur J Ophthalmol 11 Suppl 2 2001 S36 S40
109. Weinreb RN, and Levin LA Is neuroprotection a viable therapy for glaucoma? Arch Ophthalmol 117 1999 1540 1544
110. Cioffi GA, and Alm A Measurement of ocular blood flow J Glaucoma 10 Suppl 1 2001 S62 S64
111. Georgopoulos GT, Diestelhorst M, and Fisher R The short-term effect of latanoprost on intraocular pressure and pulsatile ocular blood flow Acta Ophthalmol Scand 80 2002 54 58
112. Girkin CA Strategies for neuroprotection J Glaucoma 10 Suppl 1 2001 S78 S80
113. Vajda FJ Neuroprotection and neurodegenerative disease J Clin Neuroscience 9 2002 4 8
114. Weinreb RN Neuroprotection-possibilities in perspective Surv Ophthalmol 45 Suppl 3 2001 S241 S242
115. Senst BL, Achusim LE, and Genest RP Practical approach to determining costs and frequency of adverse drug events in a health care network Am J Health Syst Pharm 58 2001 1126 1132
116. Stamper RL, Wigginton SA, and Higginbotham EJ Primary drug treatment for glaucoma: Beta-blockers versus other medications Surv Ophthalmol 47 2002 63 73
117. [package insert] Timoptic 1995 Merck & Co, Inc Savona, Italy
118. Schoene RB, Martin TR, Charan NB, and French CL Timolol-induced bronchospasm in asthmatic bronchitis JAMA 245 1981 1460 1461
119. Ananthanarayan CR, Vaile SJ, and Feldman F Acute episode of asthma following topical administration of betaxolol eyedrops Can J Ophthalmol 28 1993 80 81
120. Diggory P, Heyworth P, and Chau G Improved lung function tests on changing from topical timolol: Non-selective beta-blockade impairs lung function tests in elderly patients Eye 7 1993 661 663
121. Robin AL The role of alpha-agonists in glaucoma therapy Curr Opin Ophthalmol 8 1997 42 49
122. Loke YK, and Derry S Reporting of adverse drug reactions in randomised controlled trials--a systematic survey BMC Clin Pharmacol 1 2001 3
123. Barber BL, and Santanello NC Relating spontaneous adverse experience reports to scores on a questionnaire querying tolerability Int J Clin Pharmacol Ther 33 1995 598 604
124. Olsen H, Klemetsrud T, and Stokke HP Adverse drug reactions in current antihypertensive therapy: A general practice survey of 2586 patients in Norway Blood Press 8 1999 94 101
125. Levine M, Walter S, Lee H Evidence-Based Medicine Working Group Users' Guides to the Medical Literature. IV. How to use an article about harm JAMA 271 1994 1615 1619
126. Patel SC, and Spaeth GL Compliance in patients prescribed eyedrops for glaucoma Ophthalmic Surg 26 1995 233 236
127. Tsai JC, McClure CA, and Ramos SE Compliance barriers in glaucoma: A systematic classification J Glaucoma 12 2003 393 398
128. Kass MA, Gordon M, and Morley RE Jr Compliance with topical timolol treatment Am J Ophthalmol 103 1987 188 193
129. Kass MA, Meltzer DW, and Gordon M Compliance with topical pilocarpine treatment Am J Ophthalmol 101 1986 515 523
130. Rotchford AP, and Murphy KM Compliance with timolol treatment in glaucoma Eye 12 1998 234 236
131. Weinreb RN Therapeutics and techniques. Compliance with medical treatment of glaucoma J Glaucoma 1 1992 134 136
132. Claxton AJ, Cramer J, and Pierce C A systematic review of the associations between dose regimens and medication compliance Clin Ther 23 2001 1296 1310
133. Sverrisson T, Gross R, Pearson J United States Patient Preference Study Group International Patient Preference Study Group The dorzolamide/timolol combination versus timolol plus pilocarpine: Patient preference and impact on daily life J Glaucoma 8 1999 315 324
134. Shuttleworth A Improving drug concordance in patients with chronic conditions Nurs Times 100 2004 28 29
135. Piette JD, Richardson C, and Valenstein M Addressing the needs of patients with multiple chronic illnesses: The case of diabetes and depression Am J Manag Care 10 2004 152 162
136. Stewart WC, Chorak RP, Hunt HH, and Sethuraman G Factors associated with visual loss in patients with advanced glaucomatous changes in the optic nerve head Am J Ophthalmol 116 1993 176 181
137. Kobelt G, and Jonsson L Modeling cost of treatment with new topical treatments for glaucoma. Results from France and the United Kingdom Int J Technol Assess Health Care 15 1999 207 219
138. Fiscella RG, Geller JL, and Gryz LL Cost considerations of medical therapy for glaucoma Am J Ophthalmol 128 1999 426 433
139. Rouland J-F, Hag A, and Bengtsson S What triggers change of therapy? Jonsson B Krieglstein G Primary Open-Angle Glaucoma: Differences in International Treatment Patterns and Costs 1999 Taylor & Francis West Point, Pa
140. Bateman DN, Clark R, and Azuara-Blanco A The effects of new topical treatments on management of glaucoma in Scotland: An examination of ophthalmological health care Br J Ophthalmol 86 2002 551 554
141. Strutton DR, and Walt JG Trends in glaucoma surgery before and after the introduction of new topical glaucoma pharmacotherapies J Glaucoma 13 2004 221 226
142. Baudouin C, Rouland JF, and Le Pen C Changes in medical and surgical treatments of glaucoma between 1997 and 2000 in France Eur J Ophthalmol 13 Suppl 4 2003 S53 S60
143. Scott IU, Schein OD, and West S Functional status and quality of life measurement among ophthalmic patients Arch Ophthalmol 112 1994 329 335
144. Sherwood MB, Garcia-Siekavizza A, and Meltzer MI Glaucoma's impact on quality of life and its relation to clinical indicators. A pilot study Ophthalmology 105 1998 561 566
145. Janz NK, Wren PA, and Lichter PR Quality of life in newly diagnosed glaucoma patients: The Collaborative Initial Glaucoma Treatment Study Ophthalmology 108 2001 887 897
146. Janz NK, Wren PA, and Lichter PR The Collaborative Initial Glaucoma Treatment Study: Interim quality of life findings after initial medical or surgical treatment of glaucoma Ophthalmology 108 2001 1954 1965
147. Iester M, and Zingirian M Quality of life in patients with early, moderate and advanced glaucoma Eye 16 2002 44 49
148. Perfetti S, Varotto A, and Massagrandi S Glaucoma and quality of life Acta Ophthalmol Scand Suppl 227 1998 52
149. Wilensky JT The role of medical therapy in the rank order of glaucoma treatment Curr Opin Ophthalmol 10 1999 109 111
150. Diette GB, Skinner EA, and Nguyen TT Comparison of quality of care by specialist and generalist physicians as usual source of asthma care for children Pediatrics 108 2001 432 437
151. Donohoe MT Comparing generalist and specialty care: Discrepancies, deficiencies, and excesses Arch Intern Med 158 1998 1596 1608
152. Montouris GD How will primary care physicians, specialists, and managed care treat epilepsy in the new millennium? Neurology 55 Suppl 3 2000 S42 S44
153. Rosenblatt RA, Baldwin LM, and Chan L Improving the quality of outpatient care for older patients with diabetes: Lessons from a comparison of rural and urban communities J Fam Pract 50 2001 676 680
154. Oswald N Toyotas or hush puppies? Physician organizations and chronic care management Health Aff (Millwood) 20 2001 61 63